Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules

Details for Australian Patent Application No. 2006231622 (hide)

Owner Bristol-Myers Squibb Company

Inventors Rusnak, James; Hagerty, David

Agent A J Park

Pub. Number AU-B-2006231622

PCT Pub. Number WO2006/108035

Priority 60/668,774 06.04.05 US

Filing date 5 April 2006

Wipo publication date 12 October 2006

Acceptance publication date 5 July 2012

International Classifications

A61K 38/16 Medicinal preparations containing peptides - Peptides having more than 20 amino acids

Event Publications

11 October 2007 PCT application entered the National Phase

  PCT publication WO2006/108035 Priority application(s): WO2006/108035

5 July 2012 Application Accepted

  Published as AU-B-2006231622

1 November 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006231624-Multi-mode location based e-Directory service enabling method, system, and apparatus

2006231617-Crystal form of asenapine maleate